Inside Bar (Bearish)
|Bid||4.8100 x 1200|
|Ask||4.8200 x 1400|
|Day's Range||4.7650 - 4.9100|
|52 Week Range||2.2700 - 8.3700|
|Beta (5Y Monthly)||1.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.78|
Even if it's not a huge purchase, we think it was good to see that Jeffrey George, the Independent Director of Amneal...
Amneal (AMRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
If you're interested in Amneal Pharmaceuticals, Inc. (NYSE:AMRX), then you might want to consider its beta (a measure...
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX)Q1 2020 Earnings CallMay 11, 2020, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning and welcome to the Amneal Pharmaceuticals First Quarter 2020 Earnings Conference Call.
Amneal (AMRX) delivered earnings and revenue surprises of 150.00% and 12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 13% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 42.86% year over year to $0.20, which beat the estimate of $0.09.Revenue of $498,533,000 rose by 11.75% from the same period last year, which beat the estimate of $444,230,000.Looking Ahead Amneal Pharmaceuticals hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 11, 2020View more earnings on AMRXTime: 08:00 PM ETWebcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestors.amneal.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2160261&sessionid=1&key=E914BD59C23EF549366ECD92AF31432F®Tag=&sourcepage=registerPrice Action Company's 52-week high was at $13.66Company's 52-week low was at $2.27Price action over last quarter: Up 7.39%Company Overview Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment.See more from Benzinga * 15 Healthcare Stocks Moving In Monday's Pre-Market Session * 18 Healthcare Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Butrans® (buprenorphine) Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr. In addition, Amneal was granted the Competitive Generic Therapy (CGT) designation and 180 days of exclusivity for the 7.5 mcg/hr dose. Amneal immediately initiated commercialization activities across all dosages for its Buprenorphine Transdermal System. Butrans is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that its 2020 Annual Meeting of Stockholders (the "Annual Meeting") will be a virtual meeting instead of an in-person meeting. This change is in response to the ongoing COVID-19 pandemic and is intended to protect the health and safety of Amneal’s stockholders and employees.
Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the antimalarial drug hydroxychloroquine that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker's chief executives. Amneal has committed to producing about 20 million hydroxychloroquine tablets by mid-April, but will face challenges making any more after that because of difficulties acquiring active pharmaceutical ingredients from its supplier in Finland, co-CEOs Chirag and Chintu Patel said in an interview. "As the demand has increased all across the globe... the Finnish government has put out an emergency order to prioritize their domestic use for local needs," co-CEO Chintu Patel said in an interview on Tuesday.
Shares of generic drug makers have been pounded in recent years, pressured by lawsuits over the opioid crisis, falling prices for medicines, and other worries. Fadia argued that generic-drug pricing could rise in the short term due to scarcity created by supply-chain disruptions, and that in the long term, consumers might be willing to pay higher prices for a more secure supply. To that end, she argued, the Covid-19 crisis could result in generic drug makers bringing manufacturing back to the U.S. from India and China, where it is heavily concentrated.
The New York Times, in a major article, says Trump has a “small personal stake” in Sanofi, the French drugmaker that produces the drug. Here’s how small.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company"), one of the largest U.S.-based generics manufacturers, and the State of Texas today announced that they are responding to the national COVID-19 health emergency. Amneal has donated 1,000,000 hydroxychloroquine sulfate tablets to the Texas State Pharmacy, which will be directly distributed to hospitals for potential use in treating COVID-19 patients.
Benzinga Pro's Stocks To Watch For Wednesday * Amneal Pharmaceuticals (AMRX) \- Shares of this pharma and therapeutics maker rallied about 50% over the last five trading sessions as traders viewed the stock as a play on a controversial potential coronavirus treatment, hydroxychloroquine. Approved by the FDA for usage by patients treating malaria and lupus, President Trump has repeatedly touted the drug as a treatment for the coronavirus infection, COVID-19. But earlier clinical data on how effective hydroxychloroquine and its root chloroquine are in treating coronavirus has not been promising. In a recent study of 30 patients by a Chinese university, 13 of 15 who were given the drug as a treatment showed they didn't have the disease after a week of usage. For the remaining 15 patients in the study who did not receive the treatment, 14 no longer showed they had the disease. In addition, recent reports have suggested people may be misusing the drug without proper physician guidance in an attempt to try to prevent the coronavirus infection. The uncertainty about the drug as a potential treatment hasn't stopped companies like Amneal, Teva Pharmaceutical (TEVA) and Roche (RHHBY) from accelerating distribution and production and donating supplies to health officials. See more from Benzinga * Benzinga Pro's Stock To Watch For Fri., Mar. 20, 2020: TEVA(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Demand for hydroxychloroquine, the malaria drug that President Trump has touted as a treatment for Covid-19 despite limited evidence, has already begun to increase, according to a note from SVB Leerink analyst Ami Fadia.
Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company"), one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.